What does CUSIP 92532F100 represent in this 13F holders report?

CUSIP 92532F100 is the security identifier for VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock used to aggregate holder disclosures.

How many institutions held VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock in Q2 2017?

569 institutional investors reported VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock for Q2 2017. Use the holders table for investor-level position and value details.

VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

CUSIP: 92532F100

Q2 2017 13F Holders as of 30 Jun 2017

Type / Class: Equity / Common Stock
Shares outstanding: 254,153,218
Total 13F shares: 236,016,217
Share change: +406,711
Total reported value: $30,400,623,804
Put/Call ratio: 36%
Price per share: $128.87
Number of holders: 569
Value change: +$78,079,742
Number of buys: 303
Number of sells: 216

Quarterly Holders Quick Answers

What is CUSIP 92532F100?
CUSIP 92532F100 identifies VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2017
Previous quarter: Q1 2017

Recent filing periods for CUSIP 92532F100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	9%	22,978,643	$2,512,715,000	—	31 Mar 2017	13F
BlackRock Finance, Inc.	13F	Company	7.6%	19,246,380	$2,104,591,000	—	31 Mar 2017	13F
FMR LLC	13F	Company	7.4%	18,864,648	$2,062,849,000	—	31 Mar 2017	13F
Capital World Investors	13F	Company	7%	17,900,933	$1,957,467,000	—	31 Mar 2017	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	7%	17,765,933	$1,942,704,000	—	31 Mar 2017	13F
VANGUARD GROUP INC	13F	Company	6.5%	16,474,890	$1,801,530,000	—	31 Mar 2017	13F
STATE STREET CORP	13F	Company	4.7%	12,013,178	$1,313,647,000	—	31 Mar 2017	13F
JPMORGAN CHASE & CO	13F	Company	3.7%	9,361,376	$1,023,665,000	—	31 Mar 2017	13F
Clearbridge Investments, LLC	13F	Company	3.4%	8,754,618	$957,317,000	—	31 Mar 2017	13F
AMERIPRISE FINANCIAL INC	13F	Company	3.2%	8,238,201	$901,084,000	—	31 Mar 2017	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.4%	3,655,906	$399,774,000	—	31 Mar 2017	13F
WADDELL & REED FINANCIAL INC	13F	Company	1.4%	3,634,003	$397,379,000	—	31 Mar 2017	13F
Invesco Ltd.	13F	Company	1.2%	2,933,326	$320,758,000	—	31 Mar 2017	13F
NORTHERN TRUST CORP	13F	Company	1.1%	2,705,195	$295,813,000	—	31 Mar 2017	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.92%	2,339,821	$255,483,000	—	31 Mar 2017	13F
ORBIMED ADVISORS LLC	13F	Company	0.85%	2,169,200	$237,202,000	—	31 Mar 2017	13F
NORGES BANK	13F	Company	0.85%	2,151,921	$235,312,000	—	31 Mar 2017	13F
Bank of New York Mellon Corp	13F	Company	0.82%	2,084,232	$227,910,000	—	31 Mar 2017	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.72%	1,832,913	$200,429,000	—	31 Mar 2017	13F
MANNING & NAPIER ADVISORS LLC	13F	Company	0.69%	1,764,419	$192,938,000	—	31 Mar 2017	13F
TIAA CREF INVESTMENT MANAGEMENT LLC	13F	Company	0.64%	1,621,013	$177,258,000	—	31 Mar 2017	13F
AMUNDI ASSET MANAGEMENT US, INC.	13F	Company	0.6%	1,518,822	$166,084,000	—	31 Mar 2017	13F
BB BIOTECH AG	13F	Company	0.57%	1,455,445	$159,153,000	—	31 Mar 2017	13F
JENNISON ASSOCIATES LLC	13F	Company	0.56%	1,428,754	$156,234,000	—	31 Mar 2017	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.54%	1,366,764	$149,455,644	—	31 Mar 2017	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.52%	1,314,735	$143,767,000	—	31 Mar 2017	13F
PICTET ASSET MANAGEMENT LTD	13F	Company	0.5%	1,281,395	$140,121,000	—	31 Mar 2017	13F
FRED ALGER MANAGEMENT, LLC	13F	Company	0.48%	1,209,979	$132,311,000	—	31 Mar 2017	13F
FRANKLIN RESOURCES INC	13F	Company	0.47%	1,193,448	$130,504,000	—	31 Mar 2017	13F
DEUTSCHE BANK AG\	13F	Company	0.46%	1,174,875	$128,468,000	—	31 Mar 2017	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.46%	1,158,368	$126,668,000	—	31 Mar 2017	13F
Legal & General Group Plc	13F	Company	0.43%	1,087,943	$118,966,000	—	31 Mar 2017	13F
Tekla Capital Management LLC	13F	Company	0.41%	1,033,503	$113,014,000	—	31 Mar 2017	13F
CITADEL ADVISORS LLC	13F	Company	0.4%	1,027,654	$112,374,000	—	31 Mar 2017	13F
HealthCor Management, L.P.	13F	Company	0.4%	1,025,000	$112,084,000	—	31 Mar 2017	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.4%	1,007,060	$110,122,000	—	31 Mar 2017	13F
Swiss National Bank	13F	Company	0.35%	878,809	$96,098,000	—	31 Mar 2017	13F
Sumitomo Mitsui Trust Group, Inc.	13F	Company	0.3%	769,023	$84,093,000	—	31 Mar 2017	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.3%	751,201	$82,144,000	—	31 Mar 2017	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.29%	738,549	$80,761,000	—	31 Mar 2017	13F
CREDIT SUISSE AG/	13F	Company	0.28%	708,176	$77,439,000	—	31 Mar 2017	13F
Mitsubishi UFJ Trust & Banking Corp	13F	Company	0.26%	657,720	$71,922,000	—	31 Mar 2017	13F
Camber Capital Management LP	13F	Company	0.26%	650,000	$71,078,000	—	31 Mar 2017	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.25%	645,430	$70,578,000	—	31 Mar 2017	13F
MORGAN STANLEY	13F	Company	0.24%	604,402	$66,093,000	—	31 Mar 2017	13F
EATON VANCE MANAGEMENT	13F	Company	0.23%	575,648	$62,947,000	—	31 Mar 2017	13F
D. E. Shaw & Co., Inc.	13F	Company	0.23%	574,485	$62,820,000	—	31 Mar 2017	13F
TimesSquare Capital Management, LLC	13F	Company	0.23%	572,100	$62,559,000	—	31 Mar 2017	13F
GUGGENHEIM CAPITAL LLC	13F	Company	0.22%	570,270	$62,356,000	—	31 Mar 2017	13F
PointState Capital LP	13F	Company	0.22%	552,600	$60,427,000	—	31 Mar 2017	13F

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q2 2017

As of 30 Jun 2017, VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) was held by 569 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 236,016,217 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., FMR LLC, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, Capital World Investors, STATE STREET CORP, JPMORGAN CHASE & CO, Clearbridge Investments, LLC, and AMERIPRISE FINANCIAL INC. This page lists 570 institutional shareholders reporting positions in this security for the Q2 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2017 vs Q1 2017 Across Filers

Q1 2017 holders

512

Q2 2017 holders

569

Holder diff

Investor	Q1 2017 Shares	Q2 2017 Shares	Share Diff	Share Chg %	Q1 2017 Value $	Q2 2017 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.